The CYP3A5*1 allele has been linked to high expression of CYP3A5 and metabolism of cyclosporine. We evaluated the role of CYP3A5*1 for longterm survival in renal transplant patients in a cohort of 399 patients who underwent cadaveric or living donor kidney allograft transplantation. All patients were treated with a similar cyclosporine-based immunosuppressive maintenance therapy protocol. The mean duration of follow-up was 8.6±3.7 years. In univariate survival analysis, the presence of the CYP3A5*1 allele in recipients significantly increased patient survival P ¼ 0.028 (log-rank), resulting in a hazard ratio (HR) of 0.52 (95% CI ¼ 0.29-0.94). When the presence of the CYP3A5*1 allele was included in multivariate Cox regression analyses accounting for major risk factors for patient death, CYP3A5*1 still conferred a protective effect. Further, haplotype analysis at the CYP3A5 locus confirmed that CYP3A5*1 might indeed be responsible for this survival benefit.
Introduction
Cyclosporine-based immunosuppression therapy has become a mainstay in transplantation medicine, including kidney transplantation. 1 Calcineurin inhibitors such as cyclosporine are extensively metabolized by cytochrome P450 3A (CYP3A) enzymes. This metabolism involves CYP3A4 and CYP3A5 enzymes that represent the dominant CYP3A isoforms expressed in adult tissues. 2 Unlike CYP3A4, CYP3A5 enzyme activity shows a bimodal distribution in humans, which is attributable to a strong genetic influence that is linked to a singlenucleotide polymorphism (SNP) (A6986G) in intron 3 of CYP3A5. 2 This polymorphism disturbs correct splicing of transcripts and leads to low protein expression and enzyme activity. 3 Thus, low expression of CYP3A5 is found in homozygous carriers of the CYP3A5*3 allele, whereas homozygous and heterozygous carriers of the wild-type CYP3A5*1 allele exhibit high expression of CYP3A5. [3] [4] [5] Consequently, the metabolism and clearance of cyclosporine could be increased in carriers of the CYP3A5*1 allele.
In kidney transplant patients, it was shown that dose-adjusted steady-state blood concentrations of cyclosporine at trough were indeed significantly lower in patients carrying the CYP3A5*1 allele. 6 Nevertheless, although a significant effect of CYP3A5*1 on the metabolism and clearance of the calcineurin inhibitor tacrolimus appears well established, the clinical significance of CYP3A5*1 for cyclosporine dosing is apparently weaker and less clear. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] To account for interindividual differences in pharmacokinetics of cyclosporine close therapeutic drug monitoring has been established in clinical practice to reduce the incidence of graft rejection and its side effects, for example, nephrotoxicity. 13, 16 However, the long-term toxic effects of cyclosporine treatment on the kidney and on overall toxicity and patient survival may depend not only on blood concentrations of the parent drug, which are determined during monitoring, but also on the systemic profile of several metabolites that are not routinely measured in clinical practice. 17 Therefore, CYP3A5 activity and thus the CYP3A5*1 allele may influence toxicity and patient survival after long-term treatment with cyclosporine after transplantation. To test this hypothesis, we analyzed the influence of CYP3A5*1 on patient survival in renal transplant patients treated long term with cyclosporine in a cohort of patients who underwent kidney allograft transplantation at our renal transplant unit. 18 
Results
The overall characteristics of the renal transplant recipients cohort are presented in Table 1 . In this group of patients, the frequencies of the CYP3A5*1/*1, CYP3A5*1/*3 and CYP3A5*3/*3 genotypes (recipient: 1.5, 14.0 and 84.5%; donor: 1.3, 10.5 and 88.2%, respectively) were in agreement with the Hardy-Weinberg equilibrium as reported. 18 The recipient and donor allele frequencies for the CYP3A5*1 and CYP3A5*3 alleles were 9 and 91% or 7 and 93%, respectively. No significant differences between carriers and non-carriers of the CYP3A5*1 allele were found (Table 1) .
We first performed univariate survival analysis and observed that the presence of the CYP3A5*1 allele in recipients significantly increased patient survival P ¼ 0.028 (log-rank), resulting in a hazard ratio (HR) of 0.52 (95% CI ¼ 0.29-0.94, Figure 1a) . When the recipient CYP3A5*1 genotype was included in multivariate Cox regression analyses in which major risk factors for patient death including recipient age, systolic blood pressure and diagnosis of diabetic nephropathy were included, the CYP3A5*1 allele still conferred a protective effect (P ¼ 0.035, HR ¼ 0.52, 95% CI ¼ 0.29-0.96).
The number of deaths was overall 129 and 39 (9.8%) in carriers and 90 (22.6%) in non-carriers of CYP3A5*1. When survival of patients after graft loss in 120 patients (Figure 1b) was evaluated, the protective effect of the CYP3A5*1 was stronger in univariate analysis (P ¼ 0.003, HR ¼ 0.20, 95% CI ¼ 0.048-0.84) and was also significant in multivariate analysis (P ¼ 0.022, HR ¼ 0.24, 95% CI ¼ 0.056-1.01). The number of deaths in patients with functioning graft was higher than the death rate after graft loss, and the differences in deaths between carriers and non-carriers of CYP3A5*1 was more pronounced in patients after graft loss (3.2 vs 11.0%; P ¼ 0.04) compared to patients with functioning grafts (17.7 vs 23.4%, P ¼ NS). Patient survival after graft loss was not confounded by a difference in graft survival between genotype groups, as the CYP3A5*1 allele had no effect on long-term graft function as recently reported. 18 In addition, the presence of CYP3A5*1 in the transplant kidney had no effect on patient survival (data not shown).
Although we found no statistically significant interaction between cyclosporine dosing and CYP3A5 genotype on survival, the overall cyclosporine doses in mg per kg body CYP3A5 and patient survival in kidney transplantation weight were positively associated with overall mortality adjusted for recipient age (P ¼ 0.011). Precisely, dichotomizing at the median of 45 years and a mean dose of 3.5 mg kg À1 revealed no effect of cyclosporine dose in the group of younger patients (HR ¼ 1.33, P ¼ 0.42) unlike in the group of elder patients (HR ¼ 1.67, P ¼ 0.016). Thus, higher dosing in patients at the age above 45 years was significantly associated with shorter survival. As our analysis indicated a significant protective effect of CYP3A5*1 on mortality after graft loss when patients were treated with dialysis, we evaluated the potential protective effect of CYP3A5*1 in the second independent cohort obtained from the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) population that included only non-transplant patients treated with dialysis ( Table 2 ). The allele frequencies for the CYP3A5*1 and CYP3A5*3 alleles in this cohort were 7 and 93%, respectively, and thus comparable to those observed in the transplantation cohort. Both univariate (log-rank P ¼ 0.69) and multivariate analysis demonstrated no significant effect of CYP3A5*1 on patient survival in these patients.
Finally, we performed haplotype analysis to evaluate the possibility that SNPs in close linkage disequilibrium to the CYP3A5*1/CYP3A5*3 SNP may explain the observed protective effect on survival of transplant recipients treated with the cyclosporine-based regimen. First, the analysis of the haplotype structure of the gene cluster on human chromosome 7, including CYP3A5, CYP3A7, CYP3A4 and CYP3A43 based on data from the HapMap project, revealed that in Caucasians recombination occurs between CYP3A5 and CYP3A4, whereas CYP3A5 together with zinc-finger protein 498 and CYP3A7 fall into one linkage disequilibrium block. We genotyped two additional tagging SNPs (rs4646458 T/G and rs4646450 G/A) in the transplant cohort to capture the majority (490%) of the genetic information for this particular linkage disequilibrium block. Haplotype analysis with these two SNPs and the CYP3A5*1/CYP3A5*3 polymorphism revealed four common haplotypes ( Table 3) . The most frequent haplotype 1 accounts for more than 80% of genetic variation in this block, whereas the other three haplotypes-two of which (haplotype 3 and 4) harbor the functionally relevant CYP3A5*1 variant-capture the remaining variation. Multivariate survival analysis was repeated for all four haplotypes (Table 3) . Neither haplotype 1 nor 2 with the common CYP3A5*3 allele exhibited a survival benefit in transplant patients, whereas both haplotypes with the functionally relevant CYP3A5*1 allele confer a survival benefit in transplant patients (haplotype 3: HR ¼ 0.47. P ¼ 0.03; haplotype 4: HR ¼ 0.61, P ¼ 0.49, albeit not significant, due to the rare frequency of haplotype 4).
Discussion
In the current study, we have shown that the CYP3A5*1 allele of the CYP3A5 isoenzyme confers a survival benefit in kidney transplant patients that are chronically treated with a cyclosporine-based regimen. This effect is independent from differences in allograft survival between carriers and non-carriers of CYP3A5*1. The observed effect of CYP3A5*1 on survival was also not attributable to differences in cyclosporine dosing between carriers and non-carriers of this allele. Hence, in our previous report, we reported the data for cyclosporine dosing and demonstrated that averaged cyclosporine doses and blood concentrations at trough were not affected by the presence of CYP3A5*1.
18
The metabolism of cyclosporine by CYP3A5 takes place in the intestine during absorption and in the liver where this enzyme is predominantly expressed. 2, 19 CYP3A5 is also expressed, although at considerably lower levels compared to liver, in the human kidney where it is the major CYP3A enzyme, 4, 20 and renal expression of CYP3A5 is also strongly linked to the CYP3A5*1 allele. 4 Thus, it was important to analyze the effect of the donor genotype in the kidney on patient survival. 21 This analysis demonstrated, however, that the presence of CYP3A5*1 in the transplant kidney had no effect on patient survival, thus supporting the role of CYP3A5*1 for metabolism in the liver and intestine.
As a limitation of the current study, it is impossible to draw definite conclusions on the potential mechanisms explaining the beneficial effect of CYP3A5*1 in the transplant cohort. We detected no differences in the frequency of major causes of death, including cardiovascular diseases, infections and cancer between genotype groups, although this analysis was limited owing to the small sample size in this subgroup analysis. However, we found that the cyclosporine doses in mg per kg body weight were positively associated with overall mortality. Thus, it appears possible that the presence of CYP3A5*1 might confer its protective effect due to its additional effect on cyclosporine metabolism and the concentration pattern of cyclosporine metabolites. Indeed, more than 30 metabolites that result from the extensive biotransformation of cyclosporine by CYP3A enzymes and P-glycoprotein have been described, 17 and CYP3A5*1 may significantly contribute to the formation of primary and secondary metabolites of cyclosporine. 16 Some of these metabolites may contribute to both the immunosuppressive and toxic effects of the drug and may therefore affect graft and patient survival during chronic treatment. 16, 17 The toxic effects of cyclosporine have been well documented for several cell types in the kidney but may also apply to other cell types, for example, in the cardiovascular system and neuronal cells. 16, 17 The fact that CYP3A5*1 affects survival still after graft loss when immunosuppressive therapy has been discontinued does not rule out the possibility that CYP3A5*1 exhibits its protective effect during long-term cyclosporine treatment in patients with functioning graft by also improving their fitness and survival after graft loss.
Although it has been clearly shown that the CYP3A5*1/*3 polymorphism is both of functional relevance and frequent, the genetic evaluation of the genetic effects of CYP3A5*1 has to be considered in the context of the haplotype structure of the gene cluster on human chromosome 7, including zinc finger protein 498 (ZNF498), CYP3A5, CYP3A7, CYP3A4 and CYP3A43. 12 Moreover, polymorphisms in the CYP3A7 and CYP3A4 alleles have been shown to have functional consequences on enzyme activities and thus metabolism of substrates of these enzymes, respectively. 15 Although a potential role of CYP3A7 for cyclosporine metabolism in adult patients [22] [23] [24] appears unlikely, the CYP3A4*1B allele has been shown to increase the clearance of cyclosporine in both healthy subjects 25 and transplant patients. 26 The genetic analysis of CYP3A4*1B in the renal transplant cohort revealed an allele frequency of 6.9% and demonstrated that this SNP is not in linkage disequilibrium with the haplotype block containing CYP3A5*1 (D 0 ¼ 0.43). Thus, we performed separate survival analysis for the presence of CYP3A4*1B, which showed no significant effect on survival in renal transplant patients in crude and multivariate analysis (HR ¼ 1.1, P ¼ 0.68), respectively. In contrast, haplotype analysis indicated that the two haplotypes harboring the CYP3A5*1 allele confer a survival benefit. Furthermore, none of the other haplotypes affects survival in transplant patients. Taken together, these findings support the notion that CYP3A5*1, which is known to change the expression profile of CYP3A5, might indeed represent the variant that confers the survival benefit in transplant patients.
CYP3A5 is involved in the metabolism of many drugs and also endogenous hormones such as steroids. 2, 27 Consequently, we cannot exclude the possibility that an interaction with the CYP3A5*1/*3 polymorphism and other medications contributed to the observed effect of CYP3A5*1 on survival in transplant patients. In this regard, the strength of our studies results from the fact that all renal transplant patients were treated with the same immunosuppressive drug regimen and monitored at a single clinical center in collaboration with their home physicians (most often nephrologists). Patients who were not treated with this regimen or who were treated with additional immunosuppressive compounds or were switched to other compounds were not included in our study. Thus, the therapy regimen adhered strictly to clinical standards and an impact of switching regimens on survival is unlikely. By virtue of the nature of this long-term follow-up study, a limitation arises from the fact that the treatment of post-transplant hypertension, comorbidities and/or acute and intermittent morbidities was for obvious reasons determined by the patient's physician and not routinely monitored by our transplant unit. Thus, although we compared major risk confounders between genotype groups at baseline, we were not able to adjust for intercurrent conditions during our long-term follow-up; and can therefore not exclude a confounding impact of comorbidities on survival between genotype groups. In addition, the confounding influence of differences in drugs used in carriers and non-carriers of CYP3A5*1 cannot be excluded. In this regard, however, it is important to note that our analysis in non-transplant patients in the NECOSAD cohort excluded the possibility that the effect of CYP3A5*1 might be attributable to an overall protective effect in high-risk renal failure patients treated with non-transplant related pharmacotherapy and by dialysis. Hence, NECOSAD included only patients who were treated with dialysis as their first renal replacement therapy, whereas patients who first received dialysis and then received a transplant were censored at the date of transplantation and were thus excluded from survival analysis. 28 In this cohort, no differences in survival between carriers and non-carriers of the CYP3A5*1 allele were observed. This finding supports our conclusion that the protective effect of CYP3A5*1 on survival is specific to patients after renal transplantation. Thus, it will be important to see whether our observation can be confirmed in another transplanted population in the future.
We believe that our study points to the potential impact of pharmacogenetics for long-term prognosis of patients that goes beyond its role for individualized optimization of dosing, which is directed by monitoring blood concentrations of the parent compound. In this regard, it is important to test the role of CYP3A5*1 for survival in additional independent studies involving patients treated with cyclosporine or different substrates of CYP3A5, for example, tacrolimus. 6, 7, 9, 11 Materials and methods
Patient cohorts
Transplant patients. To test our hypothesis whether or not the presence of the CYP3A5*1 allele affects patient survival in renal transplant recipients on a cyclosporine-based therapy, we studied a cohort of renal transplant recipients as previously reported. 18 This cohort included 399 patients who underwent cadaveric or living donor kidney allograft transplantation between 1984 and 2000 at the renal transplant unit at the Benjamin Franklin Hospital (Campus Benjamin Franklin, Charité, Berlin). Individuals treated with a cyclosporine-based maintenance therapy for 10 weeks and longer after transplantation were eligible for inclusion in the study. Starting from 1984, patients were treated with the standard formulation of cyclosporine (Sandimmun) and were switched after 1995 to the microemulsion formulation (Neoral). Clinical data, including basic anthropometric, immunological and perioperative data as well as cyclosporine dose and blood concentrations, resting blood pressure and antihypertensive medication, were obtained from clinical records and from the database of the Collaborative Transplant study (CTS) and were reported previously. 18 Standard maintenance cyclosporine-based immunosuppressive therapy was performed by a triple regimen consisting of cyclosporine targeting through levels of 110-150 ng ml À1 , 5 mg day À1 prednisolone and 50 mg day À1 azathioprine or 2000 mg day À1 mycophenolate mofetil. Patients were only treated with less than the standard dosing of 50 mg azathioprine or 2000 mg mycophenolate mofetil, respectively, in cases of leucopenia CYP3A5 and patient survival in kidney transplantation or refractory cytomegalovirus infection. Patients who were treated with other immunosuppressive compounds or were switched to other compounds were not included in our study. Patients were enrolled into the registry at the time of transplantation, and data on patient survival and renal graft survival were obtained prospectively in 6 months intervals during follow-up. Loss of follow-up in the overall transplant population was below 1%. All patients were of Caucasian ethnicity. The mean duration of follow-up was 8.6 ± 3.7 years. All patients gave written informed consent to participate in the study.
Dialysis patients. We analyzed a second independent cohort to test the hypothesis whether or not the presence of CYP3A5*1 affects survival in non-transplant patients with end-stage renal disease treated with dialysis. Therefore, we evaluated the prognostic impact of CYP3A5*1 on survival of patients who were treated with dialysis and enrolled in the NECOSAD population. 28 From this cohort, we selected only Caucasian patients who were treated with dialysis as their first renal replacement therapy, whereas patients who first received dialysis and then received a transplant were censored at the date of transplantation and thus excluded from survival analysis. Overall, 399 patients from the NECOSAD cohort were available for this analysis.
Genetic analysis of SNPs
Genotyping was performed by real-time PCR using the ABI PRISM 7000 SDS instrument in conjunction with the ABI TaqMan Universal Master Mix (Applied Biosystems, Foster City, CA, USA) and was used to perform the assays. 29 Appropriate primers and fluorogenic probes were designed with the Primer Express software. Fluorogenic probes were synthesized by TIB Molbiol (Berlin, Germany) and primers were obtained from Proligo (Paris, France). The determination of the CYP3A5*1 and CYP3A5*3 alleles was performed as reported. 18 Data were analyzed using the ABI Prism 7000 SDS 1.0 Software (Perkin-Elmer, Applied Biosystems Division, Foster City, CA, USA). In addition, we evaluated the haplotype structure at the CYP3A locus for a Caucasian population available at the HapMap database (HapMap Public Release no. 19 available at http://www.hapmap.org/) and selected additional SNPs (rs4646458 and rs4646450) to perform haplotype analysis in the renal-transplant cohort. These were analyzed using pre-developed assays by Applied Biosystems. Genotyping for CYP3A4*1B was performed by restriction fragment length polymorphism as described. 30 
Statistical analysis
According to the expectation that CYP3A5*1 allele carriers have CYP3A5 enzyme activity, the CYP3A5*1/*1 and CYP3A5*1/*3 groups were analyzed together against patients with suspected low CYP3A5 activity and who are represented by the CYP3A5*3/*3 genotype. 18, 31 Thus, the influence of the CYP3A5*1 allele on patient survival was analyzed. The observed and expected allele frequencies were compared by means of the Hardy-Weinberg test.
Univariate analysis was used to construct Kaplan-Meier curves for patient survival according to the presence or absence of the CYP3A5*1 allele in both cohorts. In addition, multivariate Cox regression analyses were performed in which major risk factors for patient death were included in both cohorts. All reported P-values are two-sided and a P-value of less than 0.05 was considered to indicate statistical significance.
